Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
Manuel Sousa J, Vergara M, Pulido F, Sánchez Antolín G, Hijona L, Carnicer F, Rincón D, Salmerón J, Mateos-Muñoz B, Jou A, Polo-Lorduy B, Rubín Á, Escarda A, Aguilar P, Aldámiz-Echevarría T, García-Buey L, Carrión JA, Hernández-Guerra M, Chimeno-Hernández S, Espinosa N, Morillas RM, Andrade RJ, Delgado M, Gallego A, Magaz M, Moreno-Planas JM, Estébanez Á, Rico M, Menéndez F, Sampedro B, Morano L, Izquierdo S, Zozaya JM, Rodríguez M, Morán-Sánchez S, Lorente S, Martín-Granizo I, Von-Wichmann MÁ, Delgado M, Manzanares A. Manuel Sousa J, et al. PLoS One. 2019 Nov 12;14(11):e0225061. doi: 10.1371/journal.pone.0225061. eCollection 2019. PLoS One. 2019. PMID: 31714950 Free PMC article.
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, Bellón JM, Esteban H; GESIDA HIV/HCV cohort. Berenguer J, et al. J Antimicrob Chemother. 2009 Jun;63(6):1256-63. doi: 10.1093/jac/dkp106. Epub 2009 Apr 10. J Antimicrob Chemother. 2009. PMID: 19363085 Clinical Trial.
Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J; GESIDA3603/5607 Study Group. Berenguer J, et al. Hepatology. 2009 Aug;50(2):407-13. doi: 10.1002/hep.23020. Hepatology. 2009. PMID: 19575364
The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients.
López-Diéguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, Tural C, Hernando A, González-García J, Serrano L, Arribas JR; GESIDA 37/03-FIPSE 36465/03-NEAT IG5 Study Group. López-Diéguez M, et al. AIDS. 2011 Apr 24;25(7):899-904. doi: 10.1097/QAD.0b013e3283454174. AIDS. 2011. PMID: 21330908
Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Tural C, Solà R, Alvarez NP, Moltó J, Sánchez M, Zamora AM, Ornelas A, Laguno M, González J, von Wichmann MÁ, Téllez MJ, Paredes R, Clotet B; CORAL-2 study group. Tural C, et al. Antivir Ther. 2011;16(6):833-41. doi: 10.3851/IMP1837. Antivir Ther. 2011. PMID: 21900715 Clinical Trial.
Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
Berenguer J, von Wichmann MA, Quereda C, Miralles P, Mallolas J, López-Aldeguer J, Alvarez-Pellicer J, De Miguel J, Crespo M, Guardiola JM, Tellez MJ, Galindo MJ, Arponen S, Barquilla E, Bellón JM, González-García J; GESIDA 36/03 and 50/06 Study Groups. Berenguer J, et al. J Antimicrob Chemother. 2011 Dec;66(12):2843-9. doi: 10.1093/jac/dkr362. Epub 2011 Sep 29. J Antimicrob Chemother. 2011. PMID: 21965432
Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.
Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Jou A, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Berenguer J, et al. Clin Infect Dis. 2012 Sep;55(5):728-36. doi: 10.1093/cid/cis500. Epub 2012 May 18. Clin Infect Dis. 2012. PMID: 22610932
Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.
Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Tural C, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Barquilla E, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Berenguer J, et al. J Hepatol. 2013 Jun;58(6):1104-12. doi: 10.1016/j.jhep.2013.01.042. Epub 2013 Feb 7. J Hepatol. 2013. PMID: 23395690
Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.
Macías J, Márquez M, Téllez F, Merino D, Jiménez-Aguilar P, López-Cortés LF, Ortega E, von Wichmann MA, Rivero A, Mancebo M, Santos J, Pérez-Pérez M, Suárez-Lozano I, Romero-Palacios A, Torres-Cornejo A, Pineda JA. Macías J, et al. Clin Infect Dis. 2013 Nov;57(10):1401-8. doi: 10.1093/cid/cit537. Epub 2013 Aug 14. Clin Infect Dis. 2013. PMID: 23946224
126 results